---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001705"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:43:23.912468+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront

## Summary
- Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.
- Upfront payment of $30M; potential platform access payments up to $70M based on research continuations.
- Development and first commercial sale milestones up to $120M per target; sales milestones and tiered royalties low single digits.
- Research term at least 66 months; exclusive to AbbVie for selected tumor types during term.
- Collaboration leverages Immunome's Discovery Engine; Immunome retains platform technology rights.

## SEC filing metadata
- accession: 0001104659-23-001705
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/0001104659-23-001705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/tm231749d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001705
- JSON: https://secwatch.observer/filing/0001104659-23-001705.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001705.txt

## Key facts
- Material Agreements
  Immunome Inc. entered into Collaboration Agreement with AbbVie Global Enterprises Ltd. valued at $30 million (effective 2023-01-04).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: AbbVie Global Enterprises Ltd.
  - Value: $30 million
  - Effective: 2023-01-04
  source text: On January 4, 2023, Immunome, Inc. (the “ Company ”) entered into a collaboration and option agreement (“ Collaboration Agreement ”) with AbbVie Global Enterprises Ltd. (“ AbbVie ”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/0001104659-23-001705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.